1. Home
  2. IAG vs PRAX Comparison

IAG vs PRAX Comparison

Compare IAG & PRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Iamgold Corporation

IAG

Iamgold Corporation

N/A

Current Price

$15.27

Market Cap

8.8B

ML Signal

N/A

Logo Praxis Precision Medicines Inc.

PRAX

Praxis Precision Medicines Inc.

N/A

Current Price

$285.86

Market Cap

7.1B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
IAG
PRAX
Founded
1990
2015
Country
Canada
United States
Employees
4596
N/A
Industry
Precious Metals
Biotechnology: Pharmaceutical Preparations
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
8.8B
7.1B
IPO Year
2002
2020

Fundamental Metrics

Financial Performance
Metric
IAG
PRAX
Price
$15.27
$285.86
Analyst Decision
Buy
Strong Buy
Analyst Count
14
21
Target Price
$22.79
★ $650.00
AVG Volume (30 Days)
★ 3.6M
468.2K
Earning Date
11-05-2026
11-09-2026
Dividend Yield
N/A
N/A
EPS Growth
★ N/A
N/A
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$29.21
N/A
Revenue Next Year
$9.09
$41,442.59
P/E Ratio
$18.66
★ N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$10.87
$154.46
52 Week High
$24.87
$392.70

Technical Indicators

Market Signals
Indicator
IAG
PRAX
Relative Strength Index (RSI) 31.41 53.91
Support Level $14.78 $284.55
Resistance Level $15.64 $347.63
Average True Range (ATR) 0.70 12.62
MACD -0.14 6.37
Stochastic Oscillator 2.15 90.29

Price Performance

Historical Comparison
IAG
PRAX

About IAG Iamgold Corporation

Iamgold Corp is a mid-tier gold mining company. The company operating gold mines are divided into geographic segments such as Cote Gold mine - Canada, Burkina Faso - Essakane mine, Westwood mine - Canada. The company's s non-gold mine segments are Exploration and evaluation and development, and Corporate - which includes royalty interests. The company generates the majority of its revenue from the Cote Gold mine segment.

About PRAX Praxis Precision Medicines Inc.

Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. It is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company applies genetic insights to the discovery and development of therapies for neurological disorders through two proprietary platforms: Cerebrum and Solidus. It has established a diversified, multimodal CNS portfolio with four clinical-stage product candidates across movement disorders and epilepsy, which include Ulixacaltamide, Relutrigine, Vormatrigine, and Elsunersen. The firm operates in only one segment and is focused on discovering and developing therapies for CNS disorders.

Share on Social Networks: